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Abstract 
Glutamate is the major neurotransmitter with multiple functions in the central nervous system. Glutamate-mediated excitotoxicity 
is involved in the pathophysiological processes in schizophrenia. The purpose of this study was to determine the concentration of 
glutamate in the serum of patients with paranoid schizophrenia compared with healthy individuals, and depending on the duration 
of the schizophrenic process and leading clinical symptoms. We investigated the level of glutamate in the serum of 158 patients 
with paranoid schizophrenia and 94 healthy persons. Higher concentrations of glutamate in schizophrenic patients compared with 
healthy persons have been found. The maximum concentrations of glutamate were detected in patients with disease duration of 
more than ten years. Glutamate level in the serum does not depend on the prevailing negative or positive clinical symptoms. The 
increased concentration of glutamate can hypothetically contribute to dopaminergic and glutamatergic imbalance, leading to the 
development of psychotic symptoms and cognitive dysfunction. 
 
© 2014 The Authors. Published by Elsevier B.V. 
Peer-review under responsibility of Tomsk Polytechnic University. 
Keywords: Glutamate concentration, schizophrenia, excitotoxicity. 
 
 
 
* Corresponding author, tel: +79138291936 
E-mail: svetlana@mail.tomsknet.ru 
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Peer-review under responsibility of Tomsk Polytechnic University
Available online at www.sciencedirect.com
 S.A. Ivanova et al. /  Procedia Chemistry  10 ( 2014 )  80 – 85 81
1. Introduction 
Schizophrenia is a chronic mental illness characterized by psychotic or positive symptoms (hallucinations and 
delusions), and negative and cognitive symptoms (apathy, social withdrawal, decreased attention, decreased 
executive function, abnormal psychomotor speed of processing and impairment of verbal memory)1. Despite 
treatment advances, schizophrenia remains as a seriously disabling, lifelong illness that is among the world's top ten 
causes of long-term disability2. 
Difficulties in designing new and effective methods of diagnosis, treatment and prevention of mental illness are 
associated with a lack of understanding of the molecular mechanisms of processes involved in the development of 
the mental component of these disorders. According to the literature review most studies for the past decades have 
been conducted within the various individual hypotheses of schizophrenia pathogenesis. The neurotransmitter 
dopamine hypothesis of schizophrenia is of most current interest3,4,5. The dopamine hypothesis is based on the 
discovery that drugs that inhibit dopaminergic transmission eliminate symptoms of acute psychosis, agitation, 
anxiety and hallucinations. Dopamine was first discovered neurotransmitter involved in the mechanism of the 
disease. So far, primarily the dopamine D2-receptors, which are the most widespread dopamine receptors in the 
brain and are synthesized in a larger amount than other receptors were supposed to be involved in the pathogenesis 
of schizophrenia5.   
Although the dopamine hypothesis has been a useful model in our understanding and study of the psychotic state, 
it does not explain the deteriorating course in terms of cognition and function seen in the first few years of 
schizophrenia. Glutamate antagonists are well known to induce positive and negative psychotic symptoms more 
akin to schizophrenia than the positive symptoms induced by dopamine agonists alone6,7. It has been proposed that 
this deterioration course may be partially explained by cortical neuronal toxicity secondary to enhanced glutamate 
exposure, which in turn is thought to reflect a compensatory increase in cortical glutamatergic activity due to 
hypofunction of the N-methyl-D-aspartate (NMDA) receptor8. 
Glutamate is the most widely distributed excitatory neurotransmitter in the brain and also acts as an intermediate 
in cerebral energy metabolism9. The glutamatergic hypothesis of schizophrenia is currently well recognized, 
claiming a crucial role of the glutamate system in the genesis of schizophrenia8, although presently the underlying 
abnormalities are not fully understood. The glutamatergic abnormalities have been linked to a possible 
excitatory/inhibitory imbalance related to N-methyl-d-aspartate (NMDA) and metabotropic receptors9,10. 
Recent studies confirm the important role of glutamate in the pathophysiology and treatment of 
schizophrenia7,11,12. However, the published data on the serum concentration of this amino acid in schizophrenia are 
ambiguous and controversial8,13,14. Inconsistency of results is due to the lack of comprehensive analysis of 
complexity of this multifactorial disease. An important component of this analysis is estimation of the influence of 
the disease duration, leading negative and positive symptoms, pharmacotherapy on the concentration of glutamate. 
So, the objective of this study was investigation the glutamate concentration in schizophrenic patients, depending on 
the duration of the diseases and leading negative and positive symptoms. 
 
2. Materials and Methods 
 
    2.1. Clinical Samples 
Informed consent was obtained from each subject after explanation of the study after approval of the study 
protocol by the institutional bioethics committee. Subjects were included from two psychiatric departments (for 
permanent and temporal hospitalization) of the Mental Health Research Institute in Tomsk and Kemerovo Region 
Psychiatric Hospital.  
We included subjects with informed consent and clinical diagnosis of schizophrenia (ICD-10: F20), and excluded 
subjects with non-Caucasian physical appearance (e.g., Mongoloid, Buryats, or Khakassians), subjects with 
clinically-relevant withdrawal symptoms, and those with organic disorders. Clinical and demographic data were 
extracted from patients’ medical files.  In total, 158  Russian Caucasian patients met the inclusion criteria  aged from 
18 to 60 years (average age 37.26±12.64 years). Duration of disease is 13.37±11.08 years.  
  2.2. Medication 
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On the day of assessment and taking blood samples, a complete documentation of the medications used was 
compiled by the raters. As a psychotropic drug therapy, patients received medications as a monotherapy or 
combinations thereof: traditional antipsychotics (haloperidol, chlorprothixene, etc.), or atypical antipsychotics. The 
dose of the antipsychotic medication was converted into chlorpromazine equivalents (CPZEQ), according to the 
literature15,16. 
2.3. Laboratory examination 
The control group consisted of 94 physically and mentally healthy persons corresponding to the examined 
patients in terms of sex and age. 
Blood was taken from the cubital vein of the examined fasted persons in the morning. Glutamate concentration in 
serum was measured spectrophotometrically on the instrument Epoch (USA) using reagent kits Glutamate Assay 
Kitt (BioVision, USA). Discoloration of the solution is recorded by a spectrophotometer at λ = 450 nm. Colouring is 
proportional to the amount of glutamate in the sample. Concentration of amino acids in the examined samples is 
calculated on the basis of the calibration curve after measuring the optical density of the solution in the wells (nmol / 
μl). 
2.4.  Statistical Analysis 
Statistical Analysis has been done using statistical software SPSS 17.0 for Windows. Samples were tested for 
normality by the Shapiro-Wilk test. The significance of differences has been determined by Student t-test for 
independent samples with normal distribution; the mean and standard deviation have been calculated. When the 
distribution of independent samples was different from the normal, the significance of differences has been 
determined by U-Mann-Whitney test; the median and quartiles have been calculated. 
 
3. Results and Discussion 
 
All of the subjects, except 2, were using antipsychotics and 35 subjects (24%) were utilizing depot antipsychotics 
on the day of assessment. Table 1 presents the main demographic and clinical features of the studied population.  
 
Table 1. Basic demographic data presented as sample mean ± standard deviation or as the number (n) and the percentage (%). 
 
Characteristics 
Schizophrenic 
patients 
n=158 
Male 
n=111 
Female 
n=47 
Age, years 37.26±12.64 34.48±11.44 43.79±13.05* 
Age of the beginning of illness, years 23.87±9.66 23,59±8.14 25.15±11.22 
Duration of illness, years 13.37±11.08 11.44±8.11 18.64±14.86* 
Daily dose of antipsychotics 
(chlorpromazine equivalents) 971.8±848.6 962.8±827.0 986.6±894.3 
Subjects using atypical antipsychotics,  n  
(%) 51(34.9) 34(37.4) 17(30.9) 
Leading positive symptoms, n  (%) 92 (58.3) 64 (57.7) 28 (59.6) 
Leading negative symptoms, n  (%) 66 (41.7) 47 (42.3) 19 (40.4) 
              * p<0.0001 – significant difference between male and female. 
 
 
Serum glutamate in schizophrenic patients was significantly higher (21.35 ± 5.5 nmol/μl) compared to the 
healthy control group (13.69 ± 5.25 nmol/μl; p <0.001) (Fig. 1). Analysis of association of glutamate levels in the 
serum of schizophrenic patients with the leading positive or negative clinical symptoms showed no significant 
differences (21.28 ± 5.34 nmol/μl; 22.55 ± 4.67 nmol/μl; respectively). The maximum concentrations of glutamate 
were detected in patients with disease duration of more than ten years (Fig. 2). 
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Fig. 1. Glutamate concentration in the serum of healthy controls and patients with schizophrenia 
 (* p<0.0001 – significant difference between schizophrenic patients and healthy controls) 
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Fig. 2.  Glutamate concentration in the serum of patients with schizophrenia depending on the duration of the 
schizophrenic process (* p<0.05 - significant difference between schizophrenic patients with disease duration of 
more than 10 years and less than one year) 
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The interaction between glutamate and dopamine is widely documented3. In schizophrenia, dopaminergic 
dysregulation is thought to be the final common pathway resulting from an altered glutamatergic neurotransmission. 
Disruption of the cortical glutamatergic afferents induce decreased tonic dopamine release with a subsequent 
disinhibition of phasic dopamine release, causing abnormal responses to insignificant stimuli6.  
Glutamate concentration changes in schizophrenia could be caused by various factors, in particular, by deranged 
kinase signaling pathways. In light of the evidence of association between the mutation (N251S)-PIP5K2A and 
schizophrenia, we carried out comprehensive studies of functional regulation of neuronal PIP5K2A kinase and its 
mutants (N251S)-PIP5K2A, associated with schizophrenia, neuronal KCNQ potassium channels responsible for the 
stability of the resting potential of neurons and EAAT3 glutamate transporters preventing neurotoxic effect17. The 
new fundamental data demonstrated in Xenopus laevis oocyte expression system and in cultured human HEK293 
cells that PIP5K2A is a signaling element in the regulation of neuronal glutamate EAAT3 transporters have been 
obtained. Comparative study of functional regulation PIP5K2A and its mutant form (N251S)-PIP5K2A, associated 
with schizophrenia revealed a stimulating effect of PIP5K2A kinase on the neuronal EAAT3 glutamate transporters 
work in Xenopus laevis oocyte expression system and impairment of this function in mutant form (N251S)-
PIP5K2A. The modulation of protein expression of neuronal glutamate transporters EAAT3 by PIP5K2A kinase and 
its mutant form (N251S)-PIP5K2A, associated with schizophrenia, on Xenopus laevis oocytes membrane and in 
cultured human HEK293 cells has been detected for the first time. It was shown that diphosphorylated 
phosphoinositide PI(4,5)P2 stimulates electrogenic glutamate transport in EAAT3 expressing Xenopus laevis 
oocytes. Effects of PIP2 and PIP5K2A-coexpression EAAT3 activity are not cumulative. 
Significant functional dysregulation of neuronal KCNQ potassium channels and glutamate EAAT3 transporters 
by mutant associated with schizophrenia (N251S)-PIP5K2A kinase, greatly explains the increase in mesencephalic 
dopamine action potential in schizophrenic patients (the carriers of this mutation), as well as a metabolic disorder of 
glutamate in the brain of patients, that leads to the development of psychotic symptoms. We confirmed the 
association of polymorphic gene variant (N251S)-PIP5K2A with schizophrenia which was shown earlier in several 
independent international studies18. 
Imbalance in the functioning of the dopaminergic and glutamatergic systems is associated with the failure of 
protective neurosteroid and neurotrophic factors shown in schizophrenia and in the development of neuroleptic 
induced side effects19. Low concentrations of DHEAS found in patients with schizophrenia and especially during 
prolonged schizophrenic process, contribute to hypofunction of NMDA receptors and the development of cognitive 
dysfunction20. 
Limiting factors of our study are the following. Firstly, according to the literature, the increased glutamatergic 
excitotoxicity has been directly detected in brain structures6. We determined the glutamate concentration in the 
serum of patients. Although the blood serum glutamate level does not correlate with the cerebral glutamate level, its 
concentration in serum can be a biomarker of number of processes13. Based on the results of longstanding detiled 
research of plasma glutamatergic amino acid levels Ohnuma and Arai11 (the Juntendo University Schizophrenia 
Projects (JUSP), concluded that these amino acid levels may be diagnostic, therapeutic, or symptomatic biological 
markers. Peripheral blood levels of endogenous amino acids may reflect the degree/change in symptoms in 
schizophrenia and the status of cognitive functions in schizophrenia. 
The next limiting factor is the fact of receiving prolonged antipsychotic therapy by patients. Antipsychotic therapy 
can significantly influence the level of peripheral glutamate. The paper of van der Heijden et al.14 showed that 
glutamate at baseline was significantly higher in patients as compared to controls. During treatment, a significant 
further increase of glutamate, not related to response, was observed. Glutamate levels correlated significantly with 
negative symptom scores at baseline and weeks 3, 6 and 14.  Tortorella et al.21 demonstrated that 12 weeks of 
clozapine administration significantly reduced serum levels of glutamate but did not restore the values observed in 
normal controls, nor did it affect other amino acid concentrations. These data show changes in serum amino acids 
that may influence central serotonergic, dopaminergic and glutamatergic transmission in neuroleptic-resistant 
schizophrenics.  
 
4. Conclusion 
 
Thus, our results are consistent with literature data and confirm the possibility of the application of glutamate 
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levels in the blood serum as a biomarker for schizophrenia. Increasing the concentration of glutamate hypothetically 
contributes to the deepening of the dopaminergic and glutamatergic imbalance, leading to the development of 
psychotic symptoms, the severity of which, in turn, is associated with cognitive dysfunction. 
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